Akela Pharma achieves second milestone in Phase III cancer pain study

Akela Pharma, a drug development company focused on developing therapies for the inhalation and pain markets, has achieved the second of a series of three Fentanyl Taifun Phase III study related milestones to be paid by Janssen Pharmaceutica.